

Press release
Regulated Information

Disclosure in accordance with Belgian Law of 2 May 2007 – Transparency Law

Leuven, Belgium - 30 January 2018 – 17.45 CET - Pursuant to article 15 of the Belgian Law of 2 May 2007 regarding the publication of major holdings. ThromboGenics NV (Euronext Brussel: THR) publishes the following information:

Status as of 5 January 2018

Total capital:	€ 172,201,966.73
Total number of securities conferring voting rights:	38,271,575 shares
Total number of voting rights (denominator):	38,271,575 (one vote per share)

Reason of change

Capital increase on 5 January 2018, creation of new 2,177,226 shares fully subscribed by Novartis Pharma AG ('Novartis').

Additional Information

Capital increase was approved by the extra ordinary shareholder meeting of 20 November 2017.

This information is also available on the ThromboGenics website under 'Shareholder information' at (<http://www.thrombogenics.com/investors/shareholder-info>)

Thresholds set by the Articles of Association

According to the ThromboGenics Articles of Association the applications of Articles 6 to 17 of the Law of 2 May 2007 apply to the legal thresholds of 3%; 5% and each multiple of 5%.

Notifications

All notifications should be transmitted to both ThromboGenics nv and the FSMA. FSMA recommends transmitting notifications electronically to the email address trp.fin@fmsa.be. It is recommended to forward notifications to ThromboGenics nv electronically as well, directed to the ThromboGenics nv Company Secretary claude.sander@thrombogenics.com.

For further information please contact:

<u>ThromboGenics</u> Wouter Piepers, Global Head of Corp Coms & Investor relations +32 16 75 13 10 / +32 478 33 56 32 wouter.piepers@thrombogenics.com	<u>Citigate Dewe Rogerson</u> David Dible/ Sylvie Berrebi/ Isabelle Andrews Tel: +44 20 7638 9571 thrombogenics@citigatedewerogerson.com
---	--

About ThromboGenics

ThromboGenics is a biopharmaceutical company focused on developing innovative treatments for eye disease, with a focus on diabetic eye disease. The company's pipeline of disease modifying drug candidates is targeting the key segments of the diabetic eye disease market.

ThromboGenics' is currently evaluating THR-317, a PLGF inhibitor in a Phase I/IIa clinical study for the treatment of diabetic macular edema. Results are expected in Q1 2018. ThromboGenics' late pre-clinical pipeline consists of THR-149, a plasma kallikrein inhibitor, which has resulted from research collaboration with Bicycle Therapeutics, and THR-687, an integrin antagonist, which was in-licensed from Galapagos. THR-149 is expected to enter the clinic in the first half of 2018 and THR-687 around mid-2018. Further new drug candidates are currently being progressed for the treatment of diabetic eye disease and one of these is expected to enter development in 2018.

ThromboGenics owns the global rights to JETREA[®] (ocriplasmin), the only pharmacological vitreolysis drug approved for the treatment of symptomatic vitreomacular adhesion (in the US) and vitreomacular traction (in Europe and elsewhere).

ThromboGenics is headquartered in Leuven, Belgium, and is listed on the NYSE Euronext Brussels exchange under the symbol THR.

More information is available at www.thrombogenerics.com

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report.

This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of ThromboGenics in any jurisdiction. No securities of ThromboGenics may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.